{"id":510169,"date":"2021-07-07T08:03:26","date_gmt":"2021-07-07T12:03:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/"},"modified":"2021-07-07T08:03:26","modified_gmt":"2021-07-07T12:03:26","slug":"catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/","title":{"rendered":"Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference<\/b><\/p>\n<p>BOSTON&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.catabasis.com&amp;esheet=52455822&amp;newsitemid=20210707005084&amp;lan=en-US&amp;anchor=Catabasis+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=7e5e9ddf37652c4189e1026a89177430\">Catabasis Pharmaceuticals, Inc.<\/a> (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the upcoming virtual Ladenburg Thalmann Healthcare Conference. The presentation will take place on Tuesday, July 13<sup>th<\/sup>, 2021 at 12:30pm ET.\n<\/p>\n<p>\nA webcast of the presentation will be available at the following link: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect-us.mimecast.com%2Fs%2FgD1iCL9JjmckW03UgflVL%3Fdomain%3Dwsw-dot-yamm-track.appspot.com&amp;esheet=52455822&amp;newsitemid=20210707005084&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwsw.com%2Fwebcast%2Fladenburg7%2Fcatb%2F2378558&amp;index=2&amp;md5=7367c018b057b1b71c9ce6d5f3f4160f\">https:\/\/wsw.com\/webcast\/ladenburg7\/catb\/2378558<\/a>, and will also be available in the investors section of the Company\u2019s website, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.catabasis.com&amp;esheet=52455822&amp;newsitemid=20210707005084&amp;lan=en-US&amp;anchor=www.catabasis.com&amp;index=3&amp;md5=f9556a4602c42ee689d3180510f338ea\">www.catabasis.com<\/a>, and will be archived for 30 days following the presentation.\n<\/p>\n<p><b>About Catabasis<\/b><\/p>\n<p>\nAt Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare and niche diseases. Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210707005084r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210707005084\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210707005084\/en\/<\/a><\/span><\/p>\n<p><span class=\"bwuline\">Catabasis:<br \/>\n<\/span><br \/><b>Investor relations:<br \/>\n<\/b><br \/>Andrea Matthews<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@catabasis.com\">investors@catabasis.com<br \/>\n<\/a><\/p>\n<p><b>Media:<br \/>\n<\/b><br \/>Elizabeth Higgins<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:media@catabasis.com\">media@catabasis.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Genetics Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210707005084\/en\/565198\/3\/CATB.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference BOSTON&#8211;(BUSINESS WIRE)&#8211;Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the upcoming virtual Ladenburg Thalmann Healthcare Conference. The presentation will take place on Tuesday, July 13th, 2021 at 12:30pm ET. A webcast of the presentation will be available at the following link: https:\/\/wsw.com\/webcast\/ladenburg7\/catb\/2378558, and will also be available in the investors section of the Company\u2019s website, www.catabasis.com, and will be archived for 30 days following the presentation. About Catabasis At Catabasis Pharmaceuticals, our mission is to bring &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-510169","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference BOSTON&#8211;(BUSINESS WIRE)&#8211;Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the upcoming virtual Ladenburg Thalmann Healthcare Conference. The presentation will take place on Tuesday, July 13th, 2021 at 12:30pm ET. A webcast of the presentation will be available at the following link: https:\/\/wsw.com\/webcast\/ladenburg7\/catb\/2378558, and will also be available in the investors section of the Company\u2019s website, www.catabasis.com, and will be archived for 30 days following the presentation. About Catabasis At Catabasis Pharmaceuticals, our mission is to bring &hellip; Continue reading &quot;Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-07T12:03:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210707005084r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference\",\"datePublished\":\"2021-07-07T12:03:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\\\/\"},\"wordCount\":218,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210707005084r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\\\/\",\"name\":\"Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210707005084r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-07-07T12:03:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210707005084r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210707005084r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference - Market Newsdesk","og_description":"Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference BOSTON&#8211;(BUSINESS WIRE)&#8211;Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the upcoming virtual Ladenburg Thalmann Healthcare Conference. The presentation will take place on Tuesday, July 13th, 2021 at 12:30pm ET. A webcast of the presentation will be available at the following link: https:\/\/wsw.com\/webcast\/ladenburg7\/catb\/2378558, and will also be available in the investors section of the Company\u2019s website, www.catabasis.com, and will be archived for 30 days following the presentation. About Catabasis At Catabasis Pharmaceuticals, our mission is to bring &hellip; Continue reading \"Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-07T12:03:26+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210707005084r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference","datePublished":"2021-07-07T12:03:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/"},"wordCount":218,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210707005084r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/","name":"Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210707005084r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-07-07T12:03:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210707005084r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210707005084r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/catabasis-pharmaceuticals-to-present-at-ladenburg-thalmann-2021-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=510169"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510169\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=510169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=510169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=510169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}